Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Aortic Stenosis or Severe Aortic Regurgitation Aortic Valve Disease Aortic Valve Insufficiency Aortic Valve Stenosis Cardiovascular Diseases Heart Diseases Heart Valve Diseases Ventricular Outflow Obstruction

Age range

19 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 19 yrs
Severe aortic stenosis or severe aortic regurgitation
Agree to consent for self
Can follow-up for the next 2 years

Exclusion criteria

Pre-existing acute kidney injury
Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
On ECMO or IABP
Life expectancy < 12 months
Pregnancy

Treatment and study plan

Primary outcomes

Number of participants with adverse clinical outcomes

Time frame: Immediate post operation

Composite of all-cause death, cardiovascular mortality, and worsening of kidney function
Number of participants with adverse clinical outcomes

Time frame: 2 years after recruiting

Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2025
Study completion: 2025
First posted: Oct 1, 2020
Registry last updated: Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed